Nomura Healthcare Fund Institutional (DLHIX)
26.12
+0.54
(+2.11%)
USD |
Apr 08 2026
Returns Chart
Key Stats
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| 0.96% | 678.39M | 1.34% | 5.00% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -144.45M | 33.77% |
Basic Info
| Investment Strategy | |
| The Fund seeks maximum long-term capital growth through capital appreciation. Normally, the Fund will invest at least 80% of its assets in the equity securities of healthcare companies, meaning companies that develop, produce or distribute products or services (the "80% policy"). |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Multi Cap Core |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | Nomura Asset Management |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
34
-1.068B
Peer Group Low
20.06M
Peer Group High
1 Year
% Rank:
70
-144.45M
-2.536B
Peer Group Low
1.064B
Peer Group High
3 Months
% Rank:
53
-750.83M
Peer Group Low
1.065B
Peer Group High
3 Years
% Rank:
65
-6.922B
Peer Group Low
603.44M
Peer Group High
6 Months
% Rank:
76
-1.058B
Peer Group Low
2.547B
Peer Group High
5 Years
% Rank:
72
-8.418B
Peer Group Low
4.329B
Peer Group High
YTD
% Rank:
53
-750.83M
Peer Group Low
1.065B
Peer Group High
10 Years
% Rank:
65
-12.99B
Peer Group Low
5.908B
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of April 09, 2026.
Asset Allocation
As of February 28, 2026.
| Type | % Net |
|---|---|
| Cash | 1.11% |
| Stock | 98.15% |
| Bond | 0.74% |
| Convertible | 0.00% |
| Preferred | 0.00% |
| Other | 0.00% |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| UCB SA | 5.50% | 326.39 | 4.33% |
| Regeneron Pharmaceuticals, Inc. | 5.20% | 775.53 | 2.01% |
| Pfizer Inc. | 4.49% | 27.47 | 1.37% |
| Gilead Sciences, Inc. | 4.43% | 141.54 | 1.97% |
| Chugai Pharmaceutical Co., Ltd. | 4.27% | 57.50 | -5.66% |
| AbbVie, Inc. | 4.11% | 211.59 | 2.53% |
| AstraZeneca PLC | 3.89% | 204.27 | 1.72% |
| Eli Lilly & Co. | 3.87% | 953.30 | 2.39% |
| Merck & Co., Inc. | 3.77% | 123.18 | 3.27% |
|
Roche Holding AG
|
3.72% | -- | -- |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | -- |
| Actual Management Fee | 0.78% |
| Administration Fee | -- |
| Maximum Front Load | -- |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | -- |
| General Availability | |
| Available for Insurance Product | No |
| Available for RRSP | No |
| Purchase Details | |
| Open to New Investors |
|
| Minimum Initial Investment | 0.00 None |
| Minimum Subsequent Investment | 0.00 None |
Basic Info
| Investment Strategy | |
| The Fund seeks maximum long-term capital growth through capital appreciation. Normally, the Fund will invest at least 80% of its assets in the equity securities of healthcare companies, meaning companies that develop, produce or distribute products or services (the "80% policy"). |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Multi Cap Core |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | Nomura Asset Management |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM (4-7-26) | 2.81% |
| 30-Day SEC Yield (2-28-26) | 0.68% |
| 7-Day SEC Yield | -- |
| Number of Holdings | 110 |
| Stock | |
| Weighted Average PE Ratio | 30.19 |
| Weighted Average Price to Sales Ratio | 7.644 |
| Weighted Average Price to Book Ratio | 7.335 |
| Weighted Median ROE | 277.5% |
| Weighted Median ROA | 3.01% |
| ROI (TTM) | 5.39% |
| Return on Investment (TTM) | 5.39% |
| Earning Yield | 0.0402 |
| LT Debt / Shareholders Equity | 3.503 |
| Number of Equity Holdings | 104 |
As of February 28, 2026
Growth Metrics
| EPS Growth (1Y) | 28.02% |
| EPS Growth (3Y) | 14.32% |
| EPS Growth (5Y) | 15.29% |
| Sales Growth (1Y) | 14.52% |
| Sales Growth (3Y) | 8.76% |
| Sales Growth (5Y) | 12.51% |
| Sales per Share Growth (1Y) | 48.00% |
| Sales per Share Growth (3Y) | 8.10% |
| Operating Cash Flow - Growth Rate (3Y) | 12.12% |
As of February 28, 2026
Fund Details
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:DLHIX", "name") |
| Broad Asset Class: =YCI("M:DLHIX", "broad_asset_class") |
| Broad Category: =YCI("M:DLHIX", "broad_category_group") |
| Prospectus Objective: =YCI("M:DLHIX", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |